Corporate News
Bayer receives green light from EU authorities to use Gadovist® 1.0 in children aged two years and older
Berlin, January 27, 2012 – Bayer HealthCare successfully completed the procedure to get approval for use of the contrast medium Gadovist® 1.0 in children aged two to six years in the Europe... more
Bayer rated the most sustainable German company in its sector
One of just three chemical companies worldwide to receive Gold Class seal of quality from rating agency SAM more
Bayer HealthCare Expands Research and Manufacturing Capabilities for Interventional Franchise
Minneapolis, MN, January 19, 2012 – Bayer HealthCare announced today that it has opened a new, expanded facility for the Interventional franchise within its Medical Care’s Radiology and... more
Positive Phase III Data on Bayer’s Investigational Drug Regorafenib Show Significant Increase in Overall Survival
First presentation of data from CORRECT trial as “Late Breaking Abstract” at the 2012 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI) more
Bayer’s Xarelto® Approved in Japan for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation
Berlin, Germany, January 18, 2012 – Bayer’s once-daily oral anticoagulant Xarelto® (rivaroxaban) has been approved for the prevention of stroke and systemic embolism in patients with... more
Phase III Data of Bayer’s Regorafenib in Patients with Metastatic Colorectal Cancer to be Presented as Late Breaking Oral Presentation at 2012 ASCO-GI Congress
Late breaking abstract (LBA #385) of Phase III CORRECT study results to be presented on January 21, 2012 more
Bayer HealthCare to Share Lab Space with Start-Up Companies
Dedicated lab space-model at Bayer HealthCare U.S. Innovation Center to be called CoLaborator™ / Shared lab space will help promising life science companies get their start more
Bayer’s Xarelto® (Rivaroxaban) Submitted for U.S. Marketing Authorisation to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome
Berlin, Germany, December 29, 2011 – Bayer’s cooperation partner, Janssen Research & Development, L.L.C. has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and... more
Bayer’s Xarelto® (Rivaroxaban) Submitted for EU Marketing Authorisation for Secondary Prevention after an Acute Coronary Syndrome
Submission based on positive results of ATLAS ACS 2-TIMI 51 study / Xarelto is the only new oral anticoagulant to demonstrate significant clinical benefit in this indication when used in combination... more
Bayer: Four potential blockbusters in the Pharma pipeline
Good prospects for Xarelto™, VEGF Trap-Eye, Alpharadin and regorafenib / Market launches in the next 18 months planned / Research and development budget for 2012 approximately EUR 3 billion... more
Going to great lengths
Professional snowboarder and type 1 diabetic explores his limits at the Iron Man more
Bayer foundation provides EUR 700,000 for construction of children care facility in Japanese earthquake area
Home for orphans in Tohoku region / Bayer’s relief aid to Japan totals almost EUR 2.3 million more
Bayer Early Excellence in Science Award 2011: EUR 30,000 for young research scientists
Dr. Cristobal Uauy (John Innes Centre in Norwich, Great Britain) wins the „Biology“ category / Dr. Andreas Bender (University of Cambridge, Great Britain) takes the... more
Bayer’s Xarelto® Approved in the EU for the Prevention of Stroke in Patients with AF and in the Treatment of DVT
In stroke prevention in AF, Xarelto is the only oral anticoagulant offering patients a once-daily, highly effective therapy without need for routine coagulation monitoring / For the treatment of DVT... more
New Intrauterine System for long-term contraception submitted for marketing authorization both in the EU and the U.S.
Once approved, the new low dose IUS will offer young women contraception for up to three years more
FDA Advisory Committees affirm positive benefit-risk profile and recommend an update of US labels to reflect information from available studies
Berlin, December 9, 2011 – Bayer HealthCare today announced that at a joint meeting of the Reproductive Health Drugs Advisory Committee and the Drug Safety and Risk Management Advisory... more
Young leaders to raise awareness of diabetes
Bayer HealthCare supports the IDF Young Leaders in Diabetes Programme more
Two year results of Phase III Studies with VEGF Trap-Eye in Wet Age-related Macular Degeneration Show Sustained Improvement in Visual Acuity
Patients receiving VEGF Trap-Eye 2mg every other month achieved visual acuity gains similar to ranibizumab with, on average, five fewer injections over two years / Patients who required the most... more
Integrated diabetes software for behavioral changes and improved glycemic control
Transforming blood glucose data into meaningful insights more
Bayer and Regeneron Initiate Phase III Clinical Trial for the Treatment of Wet Age-Related Macular Degeneration in China
Berlin, Germany, and Tarrytown, NY, USA, November 28, 2011 – Bayer HealthCare and Regeneron Pharmaceuticals, Inc. today announced that they have initiated a Phase III clinical trial evaluating... more
Education can significantly improve glycaemic control
British team awarded for providing a structured pathway to reduce HbA1c levels more
2010 European Journalists' Prize goes to Dr. Britta Julia Dombrowe and John A. Kantara
Stuttgart/Leverkusen, November 22, 2011 – The Association of German Medical Journalists [Verband Deutscher Medizinjournalisten, VDMJ] presents the European Journalists’ Prize, which is... more
U.S. FDA Approves EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
Approval based on positive results of VIEW 1 and VIEW 2 clinical trials / Regeneron Pharmaceuticals will market EYLEA™ in the U.S. more
Innovations from the world of research at Bayer
Personalized medicine against cancer / Creating new active crop protection ingredients with biotechnology / Electric mobility: materials for the cars of the future more
Bayer plans further expansion in Asia
Sales in the region to grow to well over EUR 11 billion by 2015 / Some EUR 6 billion in sales expected in Greater China alone / Plans to expand production, distribution network and research / Further... more
Bayer’s Xarelto® (Rivaroxaban) Meets Primary Efficacy Endpoint and Shows Significant Reduction in Mortality in Major ACS Study
Rivaroxaban Meets Primary Efficacy Endpoint, Significantly Reducing the Composite of Cardiovascular Death, Myocardial Infarction and Stroke / Rivaroxaban 2.5 mg twice daily Significantly Reduced Both... more
Bayer cooperates with Ludwig Boltzmann Institute for Translational Heart Failure Research
Newly founded institute studies the causes of heart failure and seeks new therapeutic options more
US FDA Approves Bayer’s Xarelto® (Rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation
Rivaroxaban is highly effective and well tolerated in protecting patients with Atrial Fibrillation from stroke / Rivaroxaban is the only anticoagulant with once-daily fixed dosing for stroke... more
Bayer and AgraQuest Expand Distribution Agreement for Asia/Pacific and South America regarding Poultry Nutrition Supplement
Agreement will Allow Bayer to Distribute Patented AgraQuest Technology into Poultry Markets more
After a good third quarter: Bayer confirms Group outlook
Sales up by 4.8 percent (adjusted) to EUR 8,670 million / Continuing growth momentum in the emerging markets (adjusted: plus 9.5 percent) / Operating result (EBIT) increased by 94.9 percent to EUR... more
Phase III Trial of Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival
Trial stopped based on positive data from a pre-planned interim analysis more
Azelaic Acid is a promising treatment option for adult female acne
Adult female acne needs to be treated differently than teenage acne / Acne substantially decreases quality of life in adult women more
Bayer honors four young environmentalists from Indonesia, Ecuador, Kenya and the Philippines
Leverkusen, October 21, 2011 – The “Bayer Young Environmental Leader Award” has been presented to four students from Indonesia, Ecuador, Kenya and the Philippines. The award honors unique... more
Isoconazole nitrate shows broad antimicrobial spectrum in the treatment of superficial microbic infections
Lisbon, Portugal, October 21, 2011 – Isoconazole nitrate is not only a potent antifungal agent, but may also be effective against a broad range of bacteria which can cause bacterial... more
Bayer honors four young environmentalists from Indonesia, Ecuador, Kenya and the Philippines
Leverkusen, October 21, 2011 – The “Bayer Young Environmental Leader Award” has been presented to four students from Indonesia, Ecuador, Kenya and the Philippines. The award honors... more
New data confirm the benefits of early and first line treatment with Betaferon® in Multiple Sclerosis (MS)
Survival advantage shown in longest MS treatment trial over 21 years / Second long-term study shows low need for escalation therapy more
Ambassadors in the service of the environment visit Bayer
Around 50 young people from Africa, Asia and Latin America participate in a week-long study trip on the environment / The program is part of the partnership between Bayer and the United Nations... more
Ambassadors in the service of the environment visit Bayer
Around 50 young people from Africa, Asia and Latin America participate in a week-long study trip on the environment / The program is part of the partnership between Bayer and the United Nations... more
Bayer HealthCare and Onyx Pharmaceuticals Restructure Global Oncology Partnership
Settlement in Litigation Reached more
Contour® delivers reliable readings for diabetes self-management
Bayer’s blood glucose monitoring system exceeds ISO standard more
Phase III Study of Bayer’s Rivaroxaban in Patients with Acute Coronary Syndrome Accepted for Presentation as Late Breaker at AHA Scientific Sessions 2011
Full results of Phase III ATLAS ACS 2 TIMI 51 clinical trial to be presented on November 13, 2011 more
Bayer and UNEP honor winners of International Children's Painting Competition on the Environment
13-year-old winner from the Philippines urges global community to increase environmental protection efforts / 4 million pictures from 99 countries / Launch of the new painting competition with the... more
Bayer plans continued growth in Japan
Positive development despite earthquake and tsunami / Sales to grow by an average 6 percent annually through 2015 / Donation of EUR 700,000 for long-term reconstruction project in the earthquake zone... more
Bayer AG: Phase III Study of Bayer’s Rivaroxaban in Patients with Acute Coronary Syndrome Meets Primary Efficacy Endpoint
Leverkusen, Germany, September 29, 2011 Bayer AG announced today that the double blind, placebo controlled Phase III ATLAS ACS TIMI 51 clinical trial of Rivaroxaban plus standard therapy has met... more
MAESTRAL study: Initial results presented at the ERS congress
Avelox® (moxifloxacin HCI) successfully met primary efficacy outcome of non-inferiority in overall study population / In patients with confirmed bacterial exacerbations, moxifloxacin was associated... more
Positive Phase III Data on Bayer’s Investigational Drug Alpharadin Show Significant Increase in Overall Survival
First presentation of full data as part of Presidential Session featuring best and late-breaking abstracts at 2011 European Multidisciplinary Cancer Congress more
Bayer Partners with USAID to Make Microgynon®Fe Available and Affordable in Uganda
Launch of new public-private partnership between Bayer HealthCare and the United States Agency for International Development (USAID) / Access to Microgynon®Fe at affordable prices for middle-income... more
Xarelto® Recommended for Approval in the Prevention of AF Related Stroke and Treatment of Deep Vein Thrombosis in EU
CHMP recommends approval of rivaroxaban for two new chronic indications / Upon approval, rivaroxaban would be the only new oral anticoagulant approved in three indications in all EU member states /... more
EUR 200,000 for scholarships and teacher training
Promotion of ambitious study projects and international work experience / Emphasis on natural sciences and medicine / Hermann Strenger scholarships for career training / About EUR 938,000 already... more
Bayer CropScience presents new four pillar growth strategy: Focus on portfolio conversion, value chain, BioScience and innovation
Investment in BioScience research to double by 2015 / Accelerated portfolio conversion: Phase-out of WHO Class I products by end of 2012 more
Medrad announces initial patient enrolled in EURO CANAL study
EURO CANAL to evaluate Cotavance® paclitaxel eluting balloon with Paccocath® technology in treating critical leg ischemia below the knee more
Bayer is still a world leader in climate protection
Recognition of transparent reporting and contributions to reducing CO2 / Indices offer guidance for sustainable investment more
Bayer is still a world leader in climate protection
Recognition of transparent reporting and contributions to reducing CO2 / Indices offer guidance for sustainable investment more
Bayer and Onyx Announce New Nexavar® Data To Be Presented at the 2011 ECCO-ESMO Congress
Berlin, September 13, 2011 – Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals today announced that results from clinical trials evaluating the use of Nexavar® (sorafenib) tablets will... more
Bayer to Present New Data Evaluating Investigational Oncology Compounds at 2011 ECCO-ESMO Congress
Full results of Phase III Alpharadin trial being presented in Presidential Session I: Best and Late Breaking Abstracts / Phase II trial results evaluating Regorafenib in multiple tumor types more
Medrad receives CE Mark for Cotavance®
Launch of next generation of Cotavance paclitaxel coated balloon angioplasty catheter with Paccocath® technology / New Cotavance catheter platform includes improved paclitaxel coating process and... more
U.S. FDA Advisory Committee Recommends Approval of Bayer’s Xarelto® (Rivaroxaban)
Berlin, Germany, September 9, 2011 – Bayer HealthCare announced today that the U.S. Food and Drug Administration’s (FDA’s) Cardiovascular and Renal Drugs Advisory Committee... more
Bayer remains “best in class” in sustainability
Indices provide sustainable investors with a guide more
Bayer remains “best in class” in sustainability
Indices provide sustainable investors with a guide more
Bayer Confident in Results of ROCKET AF Study to be Reviewed by the FDA Cardiovascular and Renal Drugs Advisory Committee
Berlin, Germany, September 6, 2011 – A Cardiovascular and Renal Drugs Advisory Committee meeting has been scheduled for September 8, 2011, to review the New Drug Application in the USA for... more
Bayer Confident in Results of ROCKET AF Study to be Reviewed by the FDA Cardiovascular and Renal Drugs Advisory Committee
Berlin, Germany, September 6, 2011 – A Cardiovascular and Renal Drugs Advisory Committee meeting has been scheduled for September 8, 2011, to review the New Drug Application in the USA for... more
Bayer Healthcare to acquire Pathway Medical Technologies
Transaction complements business portfolio in vascular intervention technologies more
Bayer Healthcare to acquire Pathway Medical Technologies
Transaction complements business portfolio in vascular intervention technologies more
FDA Grants Fast Track Designation to Bayer’s Investigational Compound Alpharadin™ for the Treatment of Castration Resistant Prostate Cancer in Patients with Bone Metastases
Berlin, August 23, 2011 – Bayer HealthCare announced today that its investigational compound AlpharadinTM (radium-223 chloride), which is exclusively licensed from Algeta ASA, has been granted... more
Bayer CropScience receives approval for Liberty Link Soybeans in Argentina
Monheim, August 19, 2011 – Bayer CropScience has received the final approval for its herbicide tolerant soybean technology from the National Ministry of Agriculture in Argentina. The Liberty Link®... more
Medrad announces first use of next-generation Cotavance® catheter in research setting
Cotavance® paclitaxel eluting balloon with Paccocath® technology to be evaluated in PAD patients combined with plaque excision in DEFINITIVE™ AR study more
Bayer to support WHO and Stop Tuberculosis Partnership in fighting tuberculosis
Over 600,000 tablets of moxifloxacin to be provided for use in China more
New England Journal of Medicine Publishes Results of Landmark ROCKET AF Study of Bayer’s Xarelto® (Rivaroxaban)
Once-daily rivaroxaban successfully met primary efficacy outcome of non-inferiority in protecting patients with atrial fibrillation from stroke / In the on treatment analysis rivaroxaban was superior... more
Famine in East Africa: Bayer provides immediate aid
EUR 100,000 donated to the U.N. World Food Programme more
Famine in East Africa: Bayer provides immediate aid
EUR 100,000 donated to the U.N. World Food Programme more
Bayer among favorites for German Sustainability Award
Innovative process for production of plastics with CO2 / Jury recognizes prospect of success for use of the greenhouse gas more
Bayer continues positive momentum
Sales up 5.4 percent on an adjusted basis to EUR 9,252 million / Operating result (EBIT) advances 25.9 percent to EUR 1,273 million / EBITDA before special items increases by 5.8 percent to EUR 2,035... more
Bayer continues positive momentum
Sales up 5.4 percent on an adjusted basis to EUR 9,252 million / Operating result (EBIT) advances 25.9 percent to EUR 1,273 million / EBITDA before special items increases by 5.8 percent to EUR 2,035... more
Bayer and Trius Therapeutics to develop and commercialize new antibiotic for specific skin infections and pneumonia
Berlin, Germany, July 27, 2011 – Bayer HealthCare and Trius Therapeutics, Inc., San Diego, California, today announced that they have signed an exclusive agreement to develop and commercialize... more
Phase III J-ROCKET AF Study of Bayer’s Xarelto® (rivaroxaban) Meets Primary Endpoint
Safety of once-daily Xarelto comparable to warfarin in Japanese patients with atrial fibrillation / Results presented in the late breaking clinical trials session at the 23rd Congress of the... more
Phase III J-ROCKET AF Study of Bayer’s Xarelto® (rivaroxaban) Meets Primary Endpoint
Safety of once-daily Xarelto comparable to warfarin in Japanese patients with atrial fibrillation / Results presented in the late breaking clinical trials session at the 23rd Congress of the... more
Exercising prevents hemorrhoidal problems
www.hemorrhoid-help.com provides answers to the most frequently asked questions about sports, travelling and hemorrhoidal disease more
Azelaic acid gel improves post-inflammatory hyperpigmentation in acne patients with dark skin types
Berlin, July 12, 2011 – An open-label pilot study suggests that the application of 15% azelaic acid (AzA) gel may be a suitable treatment option for patients with skin of color with mild to... more
European Patent Office decides on Yasmin® patent challenge
Berlin, July 8, 2011 – The Board of Appeal of the European Patent Office has decided to revoke Bayer Pharma AG’s formulation patent for Yasmin®, Yasminelle® and YAZ® (EP 1214076 -... more
Bayer CropScience Settles Biotech Rice Litigation
Research Triangle Park, N.C., July 2, 2011 – Bayer CropScience has reached settlement agreements with attorneys representing U.S. long-grain rice growers in the biotech rice litigation. As agreed... more
FDA Approves Xarelto® (rivaroxaban tablets) for the Prophylaxis of Deep Vein Thrombosis Which May Lead to a Pulmonary Embolism in Patients Undergoing Knee or Hip Replacement Surgery
Xarelto® is the only new oral anticoagulant with US approval in this indication more
FDA Approves Xarelto® (rivaroxaban tablets) for the Prophylaxis of Deep Vein Thrombosis Which May Lead to a Pulmonary Embolism in Patients Undergoing Knee or Hip Replacement Surgery
Xarelto® is the only new oral anticoagulant with US approval in this indication more
Bayer advances research in the area of pulmonary hypertension
Cooperation with the Ludwig Boltzmann Institute for Lung Vascular Research / The aim is to develop new treatment options for patients with pulmonary hypertension more
VEGF Trap-Eye Submitted for Marketing Authorization for the Treatment of Wet Age-Related Macular Degeneration in Japan
Berlin, Germany and Tarrytown, NY, USA, June 29, 2011 – Bayer HealthCare and Regeneron Pharmaceuticals, Inc. today announced that Bayer Yakuhin, Ltd., Osaka, Japan, has submitted an... more
Bayer foundation scholarships – EUR 200,000 for work and study abroad
Support for ambitious study projects in the fields of science, engineering, medicine and teacher training in scientific subjects / First award of Hermann Strenger scholarships to sponsor... more
Bayer strengthens its social media presence
Leverkusen, June 10, 2011 – A special feature of Bayer’s new homepage on the social networking site Facebook is a video message from Bayer CEO Dr. Marijn Dekkers, welcoming users and... more
Alpharadin Significantly Improves Overall Survival in Phase III Trial in Patients with Castration-Resistant Prostate Cancer That Has Spread to the Bone
Trial Stopped Based on Positive Data from Pre-Planned Interim Analysis / Patients on Placebo Arm will be Offered Treatment with Alpharadin more
Alpharadin Significantly Improves Overall Survival in Phase III Trial in Patients with Castration-Resistant Prostate Cancer That Has Spread to the Bone
Trial Stopped Based on Positive Data from Pre-Planned Interim Analysis / Patients on Placebo Arm will be Offered Treatment with Alpharadin more
Peter Müller to be new Head of Finance at Bayer AG
Johannes Dietsch appointed Senior Bayer Representative in China / Bernd-Peter Bier (Taxes) and Frank Rittgen (Mergers&Acquisitions) will in future report directly to CFO Werner Baumann more
Major Subgroup Analysis Shows Bayer’s Rivaroxaban is Highly Effective in the Prevention of Recurrent Strokes
Positive benefit-risk profile of rivaroxaban in secondary prevention patients, a group who are difficult to manage and who experience the greatest complications from current anticoagulation therapy,... more
Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase II Study
Berlin, May 19, 2011 – Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced results from a Phase IIb trial evaluating Nexavar® (sorafenib) tablets in patients with... more
Bayer to Present Data on Oncology Portfolio at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO)
Presentations highlight Bayer’s growing oncology pipeline more
Nexavar Data in Multiple Tumor Types To Be Presented at 2011 American Society of Clinical Oncology Annual Meeting (ASCO)
Berlin, May 18, 2011 – Bayer HealthCare and Onyx Pharmaceuticals, Inc. today announced that studies evaluating the use of Nexavar® (sorafenib) tablets will be presented at the 2011 American... more
Phase II study with riociguat from Bayer shows promising results in patients with pulmonary hypertension owing to COPD
Data pave the way for further research with riociguat in an area of urgent unmet medical need / Additional data from preclinical studies presented highlight riociguat’s unique, dual mode of... more
Global Phase II study showed inhaled Ciprofloxacin DPI from Bayer significantly better in reducing total bacterial load compared to placebo in patients with non-cystic fibrosis bronchiectasis
Primary endpoint of reduction in mean total bacterial load in sputum versus placebo was met. / Secondary endpoints consistently favored ciprofloxacin dry powder for inhalation (DPI) over placebo. /... more
Bayer strengthens commitment to sustainable development
New climate target – reduction in specific greenhouse gas emissions by 35 percent / Health care – contraceptives made available to 16 million women in developing countries / Nutrition... more
FDA Grants Fast Track Designation to Bayer’s Investigational Compound Regorafenib for the Treatment of Gastrointestinal Stromal Tumors
Berlin, May 10, 2011 – Bayer HealthCare announced today that its investigational compound regorafenib (BAY 73-4506) has been granted Fast Track designation by the U.S. Food and Drug... more
World-class athlete Chris Southwell explores his boundaries
Type 1 diabetic and professional snowboarder is planning to compete in his first triathlon more
World-class athlete Chris Southwell explores his boundaries
Type 1 diabetic and professional snowboarder is planning to compete in his first triathlon more
Bayer MaterialScience to boost polycarbonate capacity in Europe
Increase of annual capacity of plant in Germany to 400,000 tons / EUR 90 million investment in stepped expansion at Uerdingen plant more
Bayer MaterialScience to boost polycarbonate capacity in Europe
Increase of annual capacity of plant in Germany to 400,000 tons / EUR 90 million investment in stepped expansion at Uerdingen plant more
“Our goal is to make Bayer a world-class innovative company”
Group targets achieved in 2010 / Proposal to raise dividend for 2010 to EUR 1.50 per share / Successful start to 2011 with sales and earnings gains in all subgroups / Investment for the future... more
“Our goal is to make Bayer a world-class innovative company”
Group targets achieved in 2010 / Proposal to raise dividend for 2010 to EUR 1.50 per share / Successful start to 2011 with sales and earnings gains in all subgroups / Investment for the future... more
Bayer off to a successful start to 2011
Sales up by 13.2 percent to EUR 9,415 million / Operating result (EBIT) rises by 4.0 percent to EUR 1,148 million / EBITDA before special items advances by 22.3 percent to EUR 2,232 million / Special... more
Bayer off to a successful start to 2011
Sales up by 13.2 percent to EUR 9,415 million / Operating result (EBIT) rises by 4.0 percent to EUR 1,148 million / EBITDA before special items advances by 22.3 percent to EUR 2,232 million / Special... more
Bayer and Regeneron Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
Phase 3 GALILEO study confirms results of previously announced Phase 3 COPERNICUS study more
Bayer and Regeneron Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
Phase 3 GALILEO study confirms results of previously announced Phase 3 COPERNICUS study more
Bayer to expand Companion Animal Portfolio with two new EU product approvals
First launchens in Germany and Austria to follow shortly more
Bayer to expand Companion Animal Portfolio with two new EU product approvals
First launches in Germany and Austria shortly more
Bayer affirms the positive benefit-risk profile of its drospirenone- containing oral contraceptives
Established body of well-grounded data show: VTE risk comparable in combined oral contraceptives studied more
Bayer’s Rivaroxaban Submitted for Approval in Japan
Berlin, Germany, April 14, 2011 – Bayer’s rivaroxaban (Xarelto®) has been submitted for marketing approval in the prevention of stroke in patients with atrial fibrillation to the Japanese Ministry... more
Bayer’s Rivaroxaban Submitted for Approval in Japan
Berlin, Germany, April 14, 2011 – Bayer’s rivaroxaban (Xarelto®) has been submitted for marketing approval in the prevention of stroke in patients with atrial fibrillation to the... more
Bayer and Regeneron Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
Extends ophthalmology research&development program for VEGF Trap-Eye more
Bayer and Regeneron Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
Extends ophthalmology research&development program for VEGF Trap-Eye more
Bayer Sustainable Development Report with Top Ranking
Leverkusen, April 8, 2011 – The Bayer Sustainable Development Report ranks among the best in the world. The corporate publication came in third in the category "Best Report" at this... more
In the Prevention of VTE in Acutely ill Patients, Rivaroxaban Compares Favorably with Enoxaparin but Does Not Show a Consistent Net Clinical Benefit
MAGELLAN study meets primary efficacy endpoints of demonstrating non-inferiority in short-term use and superiority in long-term use / Primary analysis shows no consistent positive benefit-risk... more
Bayer CropScience opens Seed Analytics Laboratory in Singapore
Monheim, April 4, 2011 – Bayer CropScience has opened an expanded seed research laboratory in Singapore dedicated to support the development of new high-yielding and high-quality seed varieties... more
Bayer to Present Data on Oncology Pipeline
First Presentation of Preclinical Data Evaluating Innovative Compounds, Mechanisms and PET Tracers / Presentations Highlight Growing Research and Portfolio more
Bayer again included in major sustainability indices
FTSE4Good and ASPI listings confirmed more
Bayer again included in major sustainability indices
FTSE4Good and ASPI listings confirmed more
Bayer CropScience to acquire US-based Hornbeck Seed Company
Monheim, March 23, 2011 – Bayer CropScience announced today that it has entered into an agreement to purchase Hornbeck Seed Company Inc. (HBK), a privately-held company headquartered in DeWitt,... more
Bayer and Its Employees Provide Help to Japan
Immediate Relief and Sustainable Support Worth More Than EUR 1 Million more
U.S. FDA Approves Bayer’s Gadobutrol Injection for MRI of the Central Nervous System
Berlin, March 15, 2011 – Bayer HealthCare Pharmaceuticals announced today that the U.S. Food and Drug Administration has approved Bayer’s gadobutrol injection Gadavist™... more
Bayer and Its Employees Provide Help to Japan
Immediate Relief and Sustainable Support Worth More Than EUR 1 Million more
Bayer MaterialScience to invest Euro 100 million in Germany
MDI plant Brunsbüttel: rise of production capacity to 420,000 metric tons a year more
Break the Taboo – Talk with your Doctor about your Hemorrhoid Problems!
Intendis recommends: “Stop sitting on your symptoms” and consult the new disease awareness website www.hemorrhoid-help.com more
OncoTrack: A new International consortium launches project in the area of genomic cancer diagnostics
International consortium of over 60 scientists is managed by Bayer HealthCare Pharmaceuticals and the Max Planck Institute for Molecular Genetics more
Bayer Animal Health to strengthen presence in Asia Pacific
Product launches in feed additives / Support of aquaculture business in Asia / Bomac integration to foster growth strategy more
Bayer extends support to fight Chagas disease
Company doubles donation of Lampit® tablets to ensure long-term supply of drugs more
Breaking the Taboo Associated with Hemorrhoidal Disease
Intendis launches a new disease awareness website: www.hemorrhoid-help.com “Stop sitting on your symptoms” is the claim of the initiative more
Bayer AG signs refinancing of EUR3.5bn Revolving Credit Facility
Facility closed significantly oversubscribed more
Bayer helps the victims of the natural disasters in Australia and New Zealand
The Company donates Cash and Products of more than EUR 170,000 more
Bayer helps the victims of the natural disasters in Australia and New Zealand
The Company donates Cash and Products of more than EUR 170,000 more
Bayer: operating performance on track
Group targets achieved / Strong year at MaterialScience – HealthCare and CropScience below expectations / Net income diminished by high special charges / Strong operating cash flow – net financial... more
Bayer: operating performance on track
Group targets achieved / Strong year at MaterialScience – HealthCare and CropScience below expectations / Net income diminished by high special charges / Strong operating cash flow – net... more
Bayer proposes dividend increase to EUR 1.50 per share for 2010
Leverkusen, February 24, 2011 – At its meeting today the Supervisory Board of Bayer AG accepted the proposal of the Board of Management to recommend to the Annual Stockholders’ Meeting on April... more
Bayer and Onyx Initiate Phase III Trial of Nexavar® in Combination with Chemotherapy
Berlin, February 24, 2011 – Bayer HealthCare and Onyx Pharmaceuticals, Inc. today announced that the companies have begun enrolling patients in a Phase III randomized, double-blind,... more
Bayer proposes dividend increase to EUR 1.50 per share for 2010
Leverkusen, February 24, 2011 – At its meeting today the Supervisory Board of Bayer AG accepted the proposal of the Board of Management to recommend to the Annual Stockholders’ Meeting... more
Erica L. Mann Appointed New Head of Bayer HealthCare’s Consumer Care Division
Leverkusen, February 22, 2011 – Erica L. Mann has been appointed as the new head of Bayer HealthCare´s Consumer Care Division and member of the Bayer HealthCare Executive Committee. She will... more
Bayer starts pilot plant for plastic manufacturing with CO2
High-ranking representatives attend the initiation ceremony in Leverkusen more
Bayer starts pilot plant for plastic manufacturing with CO2
High-ranking representatives attend the initiation ceremony in Leverkusen more
Journalists’ Award supports education about renal cancer
Bayer HealthCare and Kidney Cancer Association (KCA) honor outstanding medical reporting / Applications for European “Advances in Renal Cancer” Award can be submitted until March 1, 2011 more
FDA Grants Orphan Drug Designation to Regorafenib for the Treatment of Gastrointestinal Stromal Tumors
Berlin, February 4, 2011 – Bayer HealthCare announced today that its investigational anti-cancer compound regorafenib (BAY 73-4506) has been granted orphan drug status for the treatment of... more
FDA Grants Orphan Drug Designation to Regorafenib for the Treatment of Gastrointestinal Stromal Tumors
Berlin, February 4, 2011 – Bayer HealthCare announced today that its investigational anti-cancer compound regorafenib (BAY 73-4506) has been granted orphan drug status for the treatment of... more
Organizational changes at Bayer HealthCare
Streamlining administration, strengthening research and development / Handover in management of Consumer Care Division / Site consolidation at the U.S. East Coast more
Organizational changes at Bayer HealthCare
Streamlining administration, strengthening research and development / Handover in management of Consumer Care Division / Site consolidation at the U.S. East Coast more
Bayer and Zydus Cadila sign Joint Venture Agreement to strengthen pharmaceutical business in India
Berlin, January 28, 2011 – Bayer HealthCare and the Indian company Zydus Cadila signed today an agreement in Mumbai, India, to form the Joint Venture Company Bayer Zydus Pharma. With this newly... more